Arquivo

Página 1/3 1 2 3

XADAGO® (SAFINAMIDE) NOW AVAILABLE IN THE U.S. FOR PARKINSON’S DISEASE PATIENTS
11 julho 2017
ZAMBON LANÇA O XADAGO® (SAFINAMIDA) EM PORTUGAL PARA O TRATAMENTO DE DOENTES COM PARKINSON EM FASE INTERMÉDIA A AVANÇADA
10 abril 2017
Seqirus and Zambon enter into a partnership for Parkinson’s disease product in Australia and New Zealand
10 janeiro 2017
Newron re-submits US NDA for Xadago® (safinamide)
22 setembro 2016
Roberto Tascione new Ceo of Zambon
16 setembro 2016
Zambon launches Xadago® (safinamide) in Norway for patients with mid- to late-stage Parkinson's disease
01 setembro 2016
Zambon lauches Xadago® (safinamide) in the Netherlands for patients with mid-to-late-stage Parkinson’s Disease
06 julho 2016
Zambon launches XADAGO® (Safinamide) in the U.K. for patients with mid- to late-stage Parkinson’s Disease
23 maio 2016
Zambon launches Xadago® (Safinamide) in Denmark and Sweden for patients with mid-to late stage Parkinson’s Disease
28 abril 2016
Newron Pharmaceuticals and partner Zambon support Parkinson's disease Awareness Day 2016
11 abril 2016

Página 1/3 1 2 3

Notas de Imprensa

ZAMBON

PHARMA
Zambon SpA

FINE CHEMICALS
Zach System

RESEARCH VENTURE
Zcube

EUROPE

UK
Nordics

ASIA

SOUTH AMERICA

Ver más

Zambon Produtos Farmacêuticos, Lda. - ©2017, Todos os direitos reservados.
ZAMBON Prod. Farm., Lda. | Rua Comandante Enrique Maya, nº1 | 1500 - 192 Lisboa | Portugal | T. +351 217 600 952/4 | F. +351 217 600 975